This is additional protocol for biopsy specimen.
+ Optional Expert Consultation before completion of the reporting.
- Tumor histology and immunohistochemical studies:
Cannot be assessed Uninvolved by tumor, closest bone margin, specify distance (mm): Uninvolved by tumor, closest soft tissue margin, specify distance (mm): Uninvolved by tumor, closest margin, specify distance and locations (mm): Involved by invasive carcinoma, specify margins:
- The Intergroup Rhabdomyosarcoma Study Postsurgical Clinical Grouping System (Raney 2001): Not applicable Cannot be assessed (explain): Group IA: Localized tumor, confined to site of origin, completely resected Group IB:Localized tumor, infiltrating beyond site of origin, completely resected Group IIA: Localized tumor, gross total resection, but with microscopic residual disease Group IIB: Locally extensive tumor (spread to regional lymph nodes), completely resected Group IIC: Locally extensive tumor (spread to regional lymph nodes), gross total resection, but microscopic residual disease Group IIIA: Localized or locally extensive tumor, gross residual disease after biopsy only Group IIIB: Localized or locally extensive tumor, gross residual disease after major resection (greater than 50% debulking) Group IV: Any size primary tumor, with or without regional lymph node involvement, with distant metastases, without respect to surgical approach to primary tumor
- Modified Site, Size, Metastasis Staging for Rhabdomyosarcoma (Coffin 1997): Not applicable Cannot be assessed (explain): Stage I: Tumor involves favorable site (ie, bile ducts, orbit, head and neck or genitourinary site [excluding bladder, prostate, and cranial parameningeal]); and, Tumor metastatic to distant site not identified Stage II: Tumor involves unfavorable site (ie, bladder/prostate, extremity, parameningeal or other site not mentioned in stage I); and, Tumor size 5 cm or greater; and, Tumor involvement of lymph nodes not identified; and, Tumor metastatic to distant site not identified Stage III: Tumor involves unfavorable site, is 5 cm or less, and involves regional lymph nodes, but distant metastases are not identified; or, Tumor involves unfavorable site and is greater than 5 cm, with or without regional lymph node involvement, but distant metastases are not identified Stage IV: Distant metastases present
+ Additional pathologic findings: